Title: Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with temozolomide or radiation
Lead Author: Katelyn Willis
Abstract: EXTH-100
Poster presentation Saturday, November 22, 2025

SNO 2025_INBRX-109 GBM Preclinical Data

1.8 MB